ARTICLE | Finance

Synosia's POC

Synosia attracts UCB for two Parkinson's programs; adds $30M in cash

October 18, 2010 7:00 AM UTC

Synosia Therapeutics S.A. was rewarded by investors last week with a new round of financing - potentially its last before an exit - as it also announced its first out-licensing deal for two Parkinson's disease compounds with UCB Group (Euronext: